Inventaire - arkadaşlarınız ve topluluklarınız en iyi kitaplığınızdır - Inventaire

Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial

yayınlandığı: The Lancet: Diabetes & Endocrinology

yayımlanma tarihi: 2018-06-14

main subject: multicenter clinical trial, randomized experiment, Kronik böbrek hastalığı, Tip 2 diabetes mellitus, İnsülin - Glarjin

Cites articles 26

Date

Başlık

Yazarlar

2017-08-01

Liraglutide and Renal Outcomes in Type 2 Diabetes

Bernard Zinman, John Buse, Farida Valeeva
2017-06-12

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Kenneth W Mahaffey, Luis Vigil, Hanno Pijl, Ngozi Erondu
2017-09-04

GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes.

Mark M Smits, Marcel H.A. Muskiet
2016-05-15

Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program

Johan Jendle, George Grunberger
2016-10-21

Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials
2016-06-13

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

John Buse, Bernard Zinman, Farida Valeeva, Richard M Bergenstal, Steven Nissen
2016-09-15

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Anders G Holst, Tina Vilsbøll, Julio Rosenstock, Farida Valeeva
2016-06-14

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

John M. Lachin, Odd Erik Johansen, Bernard Zinman, Maximilian von Eynatten
2015-05-01

Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study.

Johan Jendle
2014-10-01

Diabetic kidney disease: a report from an ADA Consensus Conference.

Kamyar Kalantar-Zadeh, Adam T Whaley-Connell, Sankar Navaneethan
2014-02-04

Observational study of kidney function and albuminuria in patients with type 2 diabetes treated with exenatide BID versus insulin glargine

Katherine R Tuttle
2014-07-09

The potential for renoprotection with incretin-based drugs
2014-06-04

Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.

Julio Rosenstock, Bo Ahrén
2013-05-16

Effects of exenatide on kidney function, adverse events, and clinical end points of kidney disease in type 2 diabetes

Byron J. Hoogwerf, Katherine R Tuttle
2013-10-01

Effects of glucagon-like peptide-1 receptor agonists on renal function

Theodosios D. Filippatos, Moses Elisaf
2013-10-23

The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential
2013-09-01

The glucagon-like peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients
2012-11-01

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update
2012-07-01

Estimating glomerular filtration rate from serum creatinine and cystatin C.

Christopher H. Schmid, Josef Coresh
2011-05-01

Mild renal impairment and the efficacy and safety of liraglutide.
2009-05-07

Frequency of hypoglycemia and its significance in chronic kidney disease

Jeffrey C Fink
2009-05-05

A new equation to estimate glomerular filtration rate

Josef Coresh, John W Kusek, Harold I Feldman
2009-09-23

Regulation of Na+/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells

Gerhard Malnic
2007-05-01

GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting.

Jean Claude Reubi
2007-03-14

Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice.
2004-06-01

Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men.

Makale - wd:Q89128962

Welcome to Inventaire

arkadaşlarınızın ve topluluklarınızın kütüphanesi

daha fazlasını öğrenin

you are offline